https://curiecapital.nl/wp-content/uploads/2020/06/001263_SiriusMedicalPR-CErelease.pdf
Stay informed about the latest updates from Curie Capital and the ongoing activities within our portfolio companies.
- TGD001 was well tolerated with no dose-limiting toxicities across all dose cohorts, exhibiting potent thrombolytic activity -...
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as...
TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for...
Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical activity, and robust...
Quickborn, Germany and Eindhoven, Netherlands – September 24, 2025 - Mammotome, a globally recognized leader in breast care, and...
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately...